Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy

• DOI: 10.1259/bjr.20150665
• Publication Date: 2015-11-26T10:58:18Z
• Authors: Hanxi Zhao; Wanqi Zhu; Li Jia; Xiaorong Sun; Guanxuan Chen; Xianguang Zhao; Xiaolin Li; Xiangjiao Meng; Lingling Kong; Ligang Xing; Jinming Yu
• Keywords: Tolerability

The purpose of this study was to investigate the safety, tolerability and preliminary effectiveness topical epigallocatechin-3-gallate (EGCG) for radiation dermatitis in patients with breast cancer receiving adjuvant radiotherapy.Patients who received radiotherapy chest wall after mastectomy were enrolled. EGCG solution sprayed field from initiation Grade 1 until 2 weeks completion radiotherapy. concentration escalated 40 660 μmol l(-1) 7 levels 3-6 each level. toxicity graded using NCI (National Cancer Institute Common Terminology Criteria Adverse Events) v. 3.0. Any adverse event >Grade attributed considered dose-limiting toxicity. maximum tolerated dose defined as level that induced more than one-third at a given cohort. Radiation recorded weekly by Therapy Oncology Group scoring patient-reported symptoms.From March 2012 August 2013, 24 Acute skin redness observed patient be associated treatment 140 Three enrolled did not experience EGCG. escalation stopped l(-1). No other reported acute eight during or radiotherapy, but all decreased treatments. Patient-reported symptom scores significantly end pain, burning, itching tenderness, p < 0.05.The administration well found. may effective treating investigation.EGCG seemed feasible mastectomy. It should tested way reduce radiation-induced normal tissue complications future years.